| DOXORUBICIN HYDROCHLORIDE LIPOSOME | |
|---|---|
| Product Name : | DOXORUBICIN HYDROCHLORIDE LIPOSOME |
| Product Strength : | Injection 10 mg / 5.0 ml / 20mg /10ml (As Pegylated Liposome) |
| Dosage Form : | Oncology Lyophilised Injections |
| Usage : | Ovarian cancer/ Kaposi's Sarcoma/ Multiple myeloma |
| Storage Condition : | 2 - 8°C |
(Biozenta Participating in all Events)
| Events | Dates |
|---|---|
| Ghana | 16-18 May 2023 |
| Belarus (Wegworus) | 23-26 May 2023 |
| Uzbekistan (Wegwors) | 7-9 June 2023 |
| CPHI & PMEC (Shanghai) | 19-21 June 2023 |
| IPHEX Hyderabad | 5-7 July 2023 |
| Nigeria (Wegworus) | 18-20 July 2023 |
| CPHI Bangkok, Thailand | 16-18 August 2023 |
| Iran | 27-29 September 2023 |
| CPHI Worldwide (Barcelona) | 24-26 October 2023 |
| CPHI & PMEC India | 28-30 November 2023 |
Phone
